Subscribe: Latest / All - Designed by Dr James P Howard (Google+)
CIBIS-II TRIAL |
|
|---|---|
| Problem | Heart failure (Stage III or IV) |
| Format | Double-blinded multi-center RCT |
| Treatment | Bisoprolol |
| Control | Placebo |
| Population | 2647 patients |
| Inclusion criteria | Aged 18–80 years Left ventricular ejection fraction <35% NYHA class III or IV heart failure Receiving standard therapy (diuretic plus ACE inhibitor/other vasodilator) |
| Exclusion criteria | . |
| Follow-up | Median 1.3 years |
| Primary endpoint | All-cause mortality. |
| Secondary endpoint(s) | Secondary endpoints were all-cause hospital admissions, cardiovascular mortality, cardiovascular mortality and cardiovascular hospital admissions, a composite endpoint, and permanent premature treatment withdrawals. |
| Details | - |
| Brief summary: | Bisoprolol improved mortality in NYHA 3-4 |
| PAPER: The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. | |
|---|---|
| Date | 2 Jan 1999 |
| Journal | Lancet. 1999 Jan 2;353(9146):9-13. |
| Information | Significantly reduced: -All-cause mortality -All-cause hospitalisations -Sudden-death |